company background image
1AD

AdAltaASX:1AD Stock Report

Market Cap

AU$20.8m

7D

1.2%

1Y

-26.1%

Updated

25 Oct, 2021

Data

Company Financials +
1AD fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

1AD Overview

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for AdAlta
Historical stock prices
Current Share PriceAU$0.085
52 Week HighAU$0.08
52 Week LowAU$0.27
Beta1.04
1 Month Change-13.27%
3 Month Change-3.41%
1 Year Change-26.09%
3 Year Change-69.64%
5 Year Change-55.26%
Change since IPO-69.64%

Recent News & Updates

Jun 11
We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Feb 26
Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, AdAlta ( ASX:1AD...

Shareholder Returns

1ADAU BiotechsAU Market
7D1.2%-0.5%0.6%
1Y-26.1%2.5%21.3%

Return vs Industry: 1AD underperformed the Australian Biotechs industry which returned 2.5% over the past year.

Return vs Market: 1AD underperformed the Australian Market which returned 21.3% over the past year.

Price Volatility

Is 1AD's price volatile compared to industry and market?
1AD volatility
1AD Beta1.04
Industry Beta1.63
Market Beta1

Stable Share Price: 1AD is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 1AD's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006n/aTim Oldhamhttps://www.adalta.com.au

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company’s lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd.

AdAlta Fundamentals Summary

How do AdAlta's earnings and revenue compare to its market cap?
1AD fundamental statistics
Market CapAU$20.84m
Earnings (TTM)-AU$5.63m
Revenue (TTM)AU$3.98m

5.2x

P/S Ratio

-3.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1AD income statement (TTM)
RevenueAU$3.98m
Cost of RevenueAU$201.22k
Gross ProfitAU$3.78m
ExpensesAU$9.41m
Earnings-AU$5.63m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.023
Gross Margin94.95%
Net Profit Margin-141.26%
Debt/Equity Ratio26.4%

How did 1AD perform over the long term?

See historical performance and comparison

Valuation

Is AdAlta undervalued compared to its fair value and its price relative to the market?

3.26x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1AD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1AD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1AD is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: 1AD is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1AD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1AD is good value based on its PB Ratio (3.3x) compared to the AU Biotechs industry average (5x).


Future Growth

How is AdAlta forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-15.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1AD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1AD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1AD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1AD's revenue is expected to decline over the next 3 years (-11.4% per year).

High Growth Revenue: 1AD's revenue is forecast to decline over the next 3 years (-11.4% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1AD's Return on Equity is forecast to be high in 3 years time


Past Performance

How has AdAlta performed over the past 5 years?

-20.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1AD is currently unprofitable.

Growing Profit Margin: 1AD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1AD is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.

Accelerating Growth: Unable to compare 1AD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1AD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (48%).


Return on Equity

High ROE: 1AD has a negative Return on Equity (-88.13%), as it is currently unprofitable.


Financial Health

How is AdAlta's financial position?


Financial Position Analysis

Short Term Liabilities: 1AD's short term assets (A$9.0M) exceed its short term liabilities (A$2.7M).

Long Term Liabilities: 1AD has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 1AD's debt to equity ratio (26.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 1AD's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1AD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 1AD has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 17.6% each year.


Dividend

What is AdAlta current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1AD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1AD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1AD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1AD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1AD's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Tim Oldham

2yrs

Tenure

AU$499,350

Compensation

Dr. Timothy Charles Oldham, also known as Tim, B.Sc (Hons), L.L.B. (Hons), Ph D., has been Chief Executive Officer, Managing Director and Director of AdAlta Limited since October 8, 2019. Prior to this, he...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD374.33K) is about average for companies of similar size in the Australian market ($USD302.38K).

Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: 1AD's management team is considered experienced (4 years average tenure).


Board Members

Experienced Board: 1AD's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AdAlta Limited's employee growth, exchange listings and data sources


Key Information

  • Name: AdAlta Limited
  • Ticker: 1AD
  • Exchange: ASX
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$20.840m
  • Shares outstanding: 245.18m
  • Website: https://www.adalta.com.au

Location

  • AdAlta Limited
  • 2 Park Drive
  • Unit 15
  • Bundoora
  • Victoria
  • 3083
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/25 16:53
End of Day Share Price2021/10/25 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.